| Phase I Clinical Trial of BH002 in Patients With Advanced Solid Tumors (NCT06231277) | Zhuhai Beihai Biotech Co., Ltd | 2022-04-26 |
| A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours (NCT04889599) | Zhuhai Beihai Biotech Co., Ltd | 2021-04-29 |
| A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test (NCT04529122) | Hoffmann-La Roche | 2020-08-27 |
| Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours (NCT04236414) | AstraZeneca | 2020-01-14 |
| A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine (NCT04179071) | AstraZeneca | 2019-12-13 |
| Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours (NCT03415100) | The Third Affiliated Hospital of Guangzhou Medical University | 2018-01-02 |
| Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer (NCT03333824) | AstraZeneca | 2017-12-01 |
| Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours (NCT03315091) | AstraZeneca | 2017-09-29 |
| Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer (NCT03150056) | GlaxoSmithKline | 2017-07-18 |
| Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment (NCT02923947) | AstraZeneca | 2017-05-04 |
| A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR (NCT02687386) | Dr David Ziegler | 2016-02-08 |
| TOP-TRIAL Safety of Not Flushing Non-used PORT-A-CATH® in Cancer Patients (NCT02492477) | Krankenhaus Barmherzige Schwestern Linz | 2016-01-01 |
| Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours (NCT02343718) | Canadian Cancer Trials Group | 2015-06-24 |
| An Extension Study of LON002 in Patients With Cancer (NCT02390986) | LondonPharma Ltd. | 2015-01-01 |
| Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment (NCT02161770) | AstraZeneca | 2014-12-22 |
| Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors (NCT01956669) | Novartis Pharmaceuticals | 2014-10-08 |
| Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours (NCT02215850) | Welichem Biotech Inc. | 2014-10-01 |
| A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours (NCT02263950) | LondonPharma Ltd. | 2014-10-01 |
| Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours (NCT02264418) | Orion Corporation, Orion Pharma | 2014-09-18 |
| To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer (NCT02093351) | AstraZeneca | 2014-09-01 |
| To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers (NCT02093728) | AstraZeneca | 2014-04-01 |
| Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment (NCT01894243) | AstraZeneca | 2014-03-13 |
| To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects (NCT02063204) | AstraZeneca | 2014-03-01 |
| To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers (NCT02056392) | AstraZeneca | 2014-03-01 |
| To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers (NCT02046850) | AstraZeneca | 2014-02-01 |
| Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours (NCT01929603) | AstraZeneca | 2013-12-01 |
| To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers (NCT01974349) | AstraZeneca | 2013-11-01 |
| Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function (NCT01894256) | AstraZeneca | 2013-11-01 |
| To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours (NCT01900028) | AstraZeneca | 2013-10-01 |
| To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours (NCT01921140) | AstraZeneca | 2013-09-24 |
| Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly (NCT02360345) | Royal Marsden NHS Foundation Trust | 2013-09-01 |
| Tissue Collection Framework To Improve Outcomes In Solid Tumours (NCT03572192) | Queen Mary University of London | 2013-09-01 |
| Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part) (NCT01928940) | GlaxoSmithKline | 2013-08-15 |
| Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations (NCT01948297) | Debiopharm International SA | 2013-08-01 |
| D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours (NCT01851265) | AstraZeneca | 2013-07-04 |
| Phase I Trial of VS-6766 Alone and in Combination With Everolimus (NCT02407509) | Royal Marsden NHS Foundation Trust | 2013-06-17 |
| Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma (NCT01767454) | GlaxoSmithKline | 2013-02-12 |
| Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw (NCT01998607) | Amgen | 2013-02-04 |
| Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors (NCT01324258) | GlaxoSmithKline | 2011-01-24 |
| Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology (NCT01626547) | Hospira, now a wholly owned subsidiary of Pfizer | 2010-12-01 |
| A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia (NCT01184274) | NCIC Clinical Trials Group | 2010-10-01 |
| An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer (NCT01266954) | GlaxoSmithKline | 2010-06-01 |
| Utility and Work Productivity Data for Economic Evaluation of Breast Cancer Therapies in the Netherlands and Sweden (NCT01209091) | GlaxoSmithKline | 2009-08-01 |
| Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors (NCT00732420) | GlaxoSmithKline | 2008-09-24 |
| A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors (NCT00742261) | GlaxoSmithKline | 2008-08-11 |
| Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma (NCT00687622) | GlaxoSmithKline | 2008-07-28 |
| Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma (NCT00695448) | GlaxoSmithKline | 2008-06-24 |
| A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function (NCT00483860) | GlaxoSmithKline | 2007-06-20 |
| AZD1152 in Patients With Advanced Solid Malignancies-Study 3 (NCT00497679) | AstraZeneca | 2006-08-01 |
| A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors (NCT00742131) | GlaxoSmithKline | 2005-03-17 |
| Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma (NCT03702036) | GlaxoSmithKline | |